Filing Flows › Beam Therapeutics (BEAM) › Q2 2025
Beam Therapeutics (BEAM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Beam Therapeutics (BEAM) reported revenue of $8.5M for the second quarter 2025 (Q2 2025), -28% from a year earlier and +13% from the quarter before.
Beam Therapeutics, Q2 2025: revenue $8.5M (-28% year over year), net loss $102M, operating cash flow −$76.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.5M | +13% | -28% |
| Operating profit | −$120M | — | — |
| Net earnings | −$102M | — | — |
| Operating cash flow | −$76.5M | — | — |
What changed
Revenue was $8.5M in Q2 2025, down 28% year over year and up 13% from the previous quarter.
Operating costs exceeded revenue by $120.2M, an operating margin of -1419.2%. Total costs grew 10% against a revenue fall of 28%. The fastest-growing cost line was Research & development (+17%). The quarter ended with a net loss of $102.1M, narrower than the previous quarter's $108.3M loss.
Operating cash flow was −$76.5M. Non-cash charges added back $5.5M of depreciation and $24.4M of share-based compensation. Working capital and other items used $4.2M. Capital expenditures of $3.1M exceeded it, leaving free cash flow of −$79.6M.
Questions
What was Beam Therapeutics' revenue in the second quarter 2025?
Beam Therapeutics (BEAM) reported revenue of $8.5M for the second quarter 2025 (Q2 2025), -28% from a year earlier and +13% from the quarter before.
Source: Beam Therapeutics 10-Q on SEC EDGAR.